15,687 Shares of Quest Diagnostics Incorporated $DGX Acquired by Community Financial Services Group LLC

Community Financial Services Group LLC bought a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 15,687 shares of the medical research company’s stock, valued at approximately $3,625,000.

Several other large investors also recently modified their holdings of DGX. Key Financial Inc grew its stake in shares of Quest Diagnostics by 1,728.6% in the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares during the last quarter. Ancora Advisors LLC bought a new position in Quest Diagnostics during the 2nd quarter valued at approximately $29,000. Frazier Financial Advisors LLC raised its position in Quest Diagnostics by 492.9% during the 1st quarter. Frazier Financial Advisors LLC now owns 166 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 138 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in Quest Diagnostics in the 2nd quarter worth approximately $45,000. Finally, Dunhill Financial LLC purchased a new stake in Quest Diagnostics in the 2nd quarter worth approximately $46,000. 88.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DGX. Truist Financial lifted their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a research report on Monday, September 21st. Barclays boosted their target price on Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. upped their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Finally, Mizuho lifted their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $237.85.

Insider Buying and Selling

In related news, SVP Michael Prevoznik sold 22,677 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the completion of the transaction, the senior vice president owned 37,557 shares of the company’s stock, valued at $9,130,482.27. This trade represents a 37.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Delaney sold 1,600 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president directly owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This trade represents a 13.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 34,277 shares of company stock worth $8,316,493 in the last 90 days. Insiders own 0.88% of the company’s stock.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $238.92 on Friday. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $248.84. The stock has a market cap of $26.37 billion, a PE ratio of 21.94, a price-to-earnings-growth ratio of 2.11 and a beta of 0.54. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The company’s fifty day moving average price is $237.46 and its 200-day moving average price is $215.21.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the prior year, the firm earned $2.62 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities analysts expect that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be paid a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals, health plans, employers and other organizations diagnose, monitor and manage medical conditions.

Its services include routine blood and other clinical laboratory tests, advanced and molecular diagnostics, anatomic pathology, genetic and genomic testing, and testing related to infectious diseases. Quest also provides employer health screening, drug testing, clinical trial support and laboratory information services.